• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利药品政策:基本援助水平的伦理目标。

Italian drug policy: ethical aims of essential assistance levels.

作者信息

Bernardi Alessandra, Pegoraro Renzo

机构信息

Fondazione Lanza, Padova, Italy.

出版信息

Health Care Anal. 2003 Dec;11(4):279-86. doi: 10.1023/B:HCAN.0000010056.05684.22.

DOI:10.1023/B:HCAN.0000010056.05684.22
PMID:14769009
Abstract

In 2001 the Italian Government defined Essential Assistance Levels (LEA), which can be considered as an important step forward in the health care system. The Italian health care system would provide payment of essential and uniform aid services in order to safeguard many values such as human dignity, personal health, equal assistance and good health practices. The Ministry of Health has worked to rationalize the National Formulary and to define evaluation methods for drugs in order to choose what to reimburse without penalizing the rights of the individual and society. This paper describes how this job of rationalization was done and tries to illustrate the choices made in Italy by the use of two meaningful examples (statins and rivastigmine).

摘要

2001年,意大利政府确定了基本援助水平(LEA),这可被视为医疗保健系统向前迈出的重要一步。意大利医疗保健系统将提供基本且统一的援助服务费用,以维护诸多价值,如人类尊严、个人健康、平等援助和良好的健康习惯。卫生部致力于使国家药品目录合理化,并确定药品评估方法,以便在不损害个人和社会权利的情况下选择报销的药品。本文描述了这种合理化工作是如何开展的,并试图通过两个有意义的例子(他汀类药物和卡巴拉汀)来说明意大利所做出的选择。

相似文献

1
Italian drug policy: ethical aims of essential assistance levels.意大利药品政策:基本援助水平的伦理目标。
Health Care Anal. 2003 Dec;11(4):279-86. doi: 10.1023/B:HCAN.0000010056.05684.22.
2
[Statins and hypertension].
Tidsskr Nor Laegeforen. 2004 Sep 9;124(17):2277; author reply 2277.
3
[Lean years for patients].[患者的艰难岁月]
MMW Fortschr Med. 2004 Dec 16;146(51-52):16.
4
Problematic notions in Dutch health care package decisions.荷兰医疗保健套餐决策中的问题观念。
Health Care Anal. 2003 Dec;11(4):287-94. doi: 10.1023/B:HCAN.0000010057.43321.b2.
5
What price atorvastatin?阿托伐他汀价格多少?
Drug Ther Bull. 2012 Jul;50(7):73. doi: 10.1136/dtb.2012.05.0113. Epub 2012 Jul 4.
6
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].[冠心病患者使用阿托伐他汀使低密度脂蛋白水平达到100mg/dl:明年如何继续治疗?]
MMW Fortschr Med. 2004 Dec 16;146(51-52):14, 16.
7
Justice and solidarity in priority setting in health care.医疗保健资源分配中的公平与团结
Health Care Anal. 2003 Dec;11(4):325-43. doi: 10.1023/B:HCAN.0000010061.71961.87.
8
Drug policy: making effective drugs available without bankrupting the healthcare system.药品政策:提供有效的药品,同时避免医疗保健系统破产。
Healthc Pap. 2002;3(1):12-30. doi: 10.12927/hcpap.2002.16906.
9
An analysis of China's national essential medicines policy.中国国家基本药物政策分析。
J Public Health Policy. 2011 Aug;32(3):305-19. doi: 10.1057/jphp.2011.34. Epub 2011 May 26.
10
Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.通用阿托伐他汀、比利时他汀类药物市场与他汀类药物治疗的成本效益。
Cardiovasc Drugs Ther. 2013 Feb;27(1):49-60. doi: 10.1007/s10557-012-6432-y.

引用本文的文献

1
Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.贝伐珠单抗的临床应用:国家适应证与安全性相关的用药适宜性。
Oncologist. 2012;17(1):117-24. doi: 10.1634/theoncologist.2011-0184. Epub 2011 Dec 30.

本文引用的文献

1
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?药品价格会对患者潜在的自付费用做出反应吗?
Rand J Econ. 2002 Autumn;33(3):469-87.
2
[The evaluation of efficacy and efficiency in the health care sector: separate or integrated moments?].
Ann Ig. 2002 Sep-Oct;14(5):409-18.
3
Drug reimbursement: indicators of inappropriate resource allocation.药品报销:资源分配不当的指标。
Br J Clin Pharmacol. 2002 Nov;54(5):528-34. doi: 10.1046/j.1365-2125.2002.01690.x.
4
Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price.意大利的药品成本控制政策:从长远来看它们真的有效吗?最低参考价格的案例。
Health Policy. 2000 Jan;50(3):197-218. doi: 10.1016/s0168-8510(99)00070-6.
5
Capitation and risk adjustment in health care.医疗保健中的按人头付费和风险调整。
Health Care Manag Sci. 2000 Feb;3(2):73-5. doi: 10.1023/a:1019076920736.
6
An economic perspective on Alzheimer's disease.
J Geriatr Psychiatry Neurol. 1999 Spring;12(1):29-38. doi: 10.1177/089198879901200107.
7
The new pharmaceutical policy in Italy.意大利的新药品政策。
Health Policy. 1998 Oct;46(1):21-41. doi: 10.1016/s0168-8510(98)00047-5.
8
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.普伐他汀对冠心病及初始胆固醇水平范围广泛的患者心血管事件和死亡的预防作用。
N Engl J Med. 1998 Nov 5;339(19):1349-57. doi: 10.1056/NEJM199811053391902.
9
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.普伐他汀对胆固醇水平正常的心肌梗死患者冠状动脉事件的影响。胆固醇与再发事件试验研究人员。
N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.
10
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).4444例冠心病患者降胆固醇随机试验:斯堪的纳维亚辛伐他汀生存研究(4S)
Lancet. 1994 Nov 19;344(8934):1383-9.